Follow up of multiple myeloma patients with renal impairment during a 10 year period
2012 (English)Conference paper (Other academic)
Background. Renal impairment (RI) is a relatively common feature of multiplemyeloma (MM) and it has been shown in several studies that RI at diagnosiscorrelates to inferior survival, significant morbidity and increased early deathrate. Aims. To compare the efficacy of bortezomib-based treatment to otheranti-myeloma treatments during the course of the disease in patients presentingwith creatinine ≥130 μmol/L. The primary endpoint of the study was renalresponse (RR) in 1st, 2nd and 3rd line treatment. Time to progression (TTP), timeto next treatment (TTNT), overall survival (OS) and MM response were thesecondary endpoints.
Place, publisher, year, edition, pages
Pavia: Ferrata Storti Foundation, 2012. Vol. 97, no supplement 1, 599-599 p.
, Haematologica, ISSN 0390-6078 ; Volume 97, supplement 1
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:kth:diva-141418OAI: oai:DiVA.org:kth-141418DiVA: diva2:696667
17th congress of European Hematology Association, EHA, June 14-17 2012, Amsterdam, The Netherlands
QC 201502102014-02-142014-02-142015-02-10Bibliographically approved